NZ596780A - Immunoregulatory peptides and methods of use - Google Patents

Immunoregulatory peptides and methods of use

Info

Publication number
NZ596780A
NZ596780A NZ596780A NZ59678010A NZ596780A NZ 596780 A NZ596780 A NZ 596780A NZ 596780 A NZ596780 A NZ 596780A NZ 59678010 A NZ59678010 A NZ 59678010A NZ 596780 A NZ596780 A NZ 596780A
Authority
NZ
New Zealand
Prior art keywords
methods
peptides
disclosed
immunoregulatory peptides
toll
Prior art date
Application number
NZ596780A
Other languages
English (en)
Inventor
Sharon L Mccoy
Steven H Hefeneider
Original Assignee
13Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 13Therapeutics Inc filed Critical 13Therapeutics Inc
Publication of NZ596780A publication Critical patent/NZ596780A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C07K14/07—Vaccinia virus; Variola virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ596780A 2009-06-05 2010-06-04 Immunoregulatory peptides and methods of use NZ596780A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18445509P 2009-06-05 2009-06-05
US18443809P 2009-06-05 2009-06-05
US22073809P 2009-06-26 2009-06-26
US22074509P 2009-06-26 2009-06-26
US25636409P 2009-10-30 2009-10-30
PCT/US2010/037443 WO2010141845A2 (en) 2009-06-05 2010-06-04 Immunoregulatory peptides and methods of use

Publications (1)

Publication Number Publication Date
NZ596780A true NZ596780A (en) 2013-04-26

Family

ID=43298558

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596780A NZ596780A (en) 2009-06-05 2010-06-04 Immunoregulatory peptides and methods of use

Country Status (9)

Country Link
US (5) US8450285B2 (enExample)
EP (1) EP2437772B1 (enExample)
JP (1) JP5797191B2 (enExample)
CN (1) CN102803500B (enExample)
AU (1) AU2010256445B2 (enExample)
CA (1) CA2764164A1 (enExample)
MX (1) MX2011012875A (enExample)
NZ (1) NZ596780A (enExample)
WO (1) WO2010141845A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2437772B1 (en) 2009-06-05 2017-12-06 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
TWI609889B (zh) * 2016-05-11 2018-01-01 偉喬生醫股份有限公司 提升蛋白質遞送至細胞內之效率的蛋白標籤及方法
KR101943978B1 (ko) * 2017-12-28 2019-01-30 주식회사 하이센스바이오 신규한 펩타이드
CN109456390B (zh) * 2018-12-27 2021-11-16 西华师范大学 一种人工合成多肽h-473及其应用
KR20230100729A (ko) * 2020-10-30 2023-07-05 푸단 유니버시티 면역반응 조절 또는 항종양 약물 제조에 있어 itpripl1 조절제의 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000515A1 (en) 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
DK0554284T3 (da) 1990-10-24 1997-01-06 Allelix Biopharma Peptid-baserede hæmmere af Hiv-replikation
CA2094658A1 (en) 1992-04-23 1993-10-24 Martin Sumner-Smith Intracellular delivery of biochemical agents
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
US6228344B1 (en) 1997-03-13 2001-05-08 Mallinckrodt Inc. Method of measuring physiological function
ES2210761T3 (es) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6093417A (en) 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
WO2001013957A2 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6835713B2 (en) * 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
EP1385872A4 (en) * 2001-05-11 2004-12-15 Res Dev Foundation NF-KAPPA B ACTIVATOR RECEPTOR INHIBITORS AND USES OF SUCH INHIBITORS
EP1412390A2 (en) * 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
JP2006509724A (ja) * 2002-08-01 2006-03-23 ワイス 炎症及びアポトーシスに関係する方法及び試薬
AU2003264836A1 (en) * 2002-09-05 2004-03-29 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Orthopoxvirus vectors, genes and products thereof
CA2520655A1 (en) 2003-04-08 2004-11-04 Biotempt, B.V. Compositions for mucosal and oral administration comprising hcg fragments
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7192930B2 (en) * 2004-07-12 2007-03-20 U.S. Department Of Veterans Affairs Method and peptide for regulating cellular activity
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
AU2007233116B2 (en) * 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US20080039395A1 (en) 2006-08-07 2008-02-14 United States Government As Represented By The Department Of Veterans Affairs Methods for treating septic shock
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8722052B2 (en) * 2008-11-17 2014-05-13 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Vaccinia virus protein A46 peptide and use thereof
EP2437772B1 (en) 2009-06-05 2017-12-06 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing

Also Published As

Publication number Publication date
US20160250320A1 (en) 2016-09-01
WO2010141845A8 (en) 2011-12-01
JP5797191B2 (ja) 2015-10-21
WO2010141845A2 (en) 2010-12-09
JP2012528891A (ja) 2012-11-15
MX2011012875A (es) 2012-02-28
AU2010256445A1 (en) 2011-12-22
AU2010256445B2 (en) 2015-07-30
EP2437772A4 (en) 2013-07-10
WO2010141845A9 (en) 2011-06-23
US9974853B2 (en) 2018-05-22
US20130203679A1 (en) 2013-08-08
EP2437772A1 (en) 2012-04-11
US8450285B2 (en) 2013-05-28
CA2764164A1 (en) 2010-12-09
US20100317564A1 (en) 2010-12-16
EP2437772B1 (en) 2017-12-06
US20130203683A1 (en) 2013-08-08
US9150616B2 (en) 2015-10-06
US20130210741A1 (en) 2013-08-15
CN102803500B (zh) 2014-11-19
US9187530B2 (en) 2015-11-17
US9150617B2 (en) 2015-10-06
CN102803500A (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
AU2018253546A1 (en) Aromatic-cationic peptides and methods for using same
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
NZ602734A (en) Therapeutic dll4 binding proteins
MY185206A (en) Therapeutically active compounds and their methods of use
WO2013061083A3 (en) Therapeutic agents and uses thereof
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
NZ702469A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MY188139A (en) Sodium channel modulators for the treatment of pain
GB201111485D0 (en) Drug composition and its use in therapy
MX2011012875A (es) Peptidos inmunoreguladores y metodos de uso.
MX360030B (es) Metodos para tratar el trastorno bipolar.
IL198743A0 (en) Transdermal therapeutic system for administering the active substance buprenorphine
WO2014028396A3 (en) Therapeutic elastic tape
MX2014004459A (es) Inhibidores de peptidos de la proteina precursora amiloide de sitio b que escinde la enzima 1 (bace1).
MX2013008530A (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
WO2012138879A3 (en) Peptides for the treatment of hearing
PH12014500739B1 (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines
NZ598124A (en) Compounds for treatment of inflammation
WO2012009640A3 (en) B cell depletion for central nervous system injuries and methods and uses thereof
PH12013501638A1 (en) (5s,8s)-3-(4`-chlor-3`-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for treatment
AU2012339225A8 (en) Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
UA67427U (ru) Способ лечения фиброзно-кавернозных форм органного туберкулеза

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 JUN 2017 BY CPA GLOBAL

Effective date: 20140508

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20171018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 JUN 2020 BY COMPUTER PACKAGES INC

Effective date: 20191018

LAPS Patent lapsed